Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

Nuvo Research Inc. (T:NRI)

Business Focus: N/A

Get the company report for the most recent outlook updated daily
Jul 29, 2021 05:05 pm ET
Miravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea
- First Asian Partnering Deal for Suvexx - - Up to EUR 1.1 million in upfront and milestone payments -  
Jul 29, 2021 05:05 pm ET
Miravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea
- First Asian Partnering Deal for Suvexx - - Up to EUR 1.1 million in upfront and milestone payments -  
Dec 21, 2020 06:30 am ET
Miravo Healthcare™ Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select EU Markets
- First European Partnering Deal for Suvexx -- Up to EUR 1.7 million in upfront and milestone payments -  
Dec 21, 2020 06:30 am ET
Miravo Healthcare™ Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select EU Markets
- First European Partnering Deal for Suvexx -- Up to EUR 1.7 million in upfront and milestone payments -  
Dec 18, 2020 06:30 am ET
Nuvo Pharmaceuticals® Announces Corporate Rebranding as Miravo Healthcare™
- Consolidates to One Single Corporate Brand Identity -
Dec 18, 2020 06:30 am ET
Nuvo Pharmaceuticals® Announces Corporate Rebranding as Miravo Healthcare™
- Consolidates to One Single Corporate Brand Identity -
Nov 16, 2020 06:30 am ET
Nuvo Pharmaceuticals® Announces Third Quarter 2020 Results
 
Nov 16, 2020 06:30 am ET
Nuvo Pharmaceuticals® Announces Third Quarter 2020 Results
 
Nov 02, 2020 06:30 am ET
Nuvo Pharmaceuticals™ Announces Third Quarter 2020 Results Release Date and Conference Call Details
MISSISSAUGA, ON, Nov. 2, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2020 financial results before markets open on Monday, November 16, 2020.
Nov 02, 2020 06:30 am ET
Nuvo Pharmaceuticals™ Announces Third Quarter 2020 Results Release Date and Conference Call Details
MISSISSAUGA, ON, Nov. 2, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2020 financial results before markets open on Monday, November 16, 2020.
Oct 12, 2020 08:35 am ET
Growth Company Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Oct 05, 2020 09:58 am ET
Live Growth Opportunities Investor Conference October 8th
Company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Oct 05, 2020 07:30 am ET
Nuvo Pharmaceuticals® to Webcast Live at VirtualInvestorConferences.com October 8th
- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com -
Sep 21, 2020 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...
Sep 14, 2020 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Sep 14, 2020 08:30 am ET
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum September 17th
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Jesse Ledger, Nuvo’s President & Chief Executive...
Sep 14, 2020 07:30 am ET
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum September 17th
- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com -
Sep 09, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces The Canadian Commercial Launch of Suvexx™ - For The Acute Treatment of Migraine
- Combination of sumatriptan succinate and naproxen sodium in a single tablet -
Aug 10, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces Second Quarter 2020 Results
٠ Q2 2020 Adjusted Total Revenue - $18.0 million ٠٠ Q2 2020 Adjusted EBITDA - $7.6 million ٠٠ Blexten Canadian Prescriptions Increased 34% Year-Over-Year ٠٠ Cambia Canadian Prescriptions Increased 11% Year-Over-Year ٠
Jul 27, 2020 07:30 am ET
Nuvo Pharmaceuticals™ Announces Second Quarter 2020 Results Release Date and Conference Call Details
MISSISSAUGA, ON, July 27, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2020 financial results before markets open on Monday, August 10, 2020.
Jul 27, 2020 07:30 am ET
Nuvo Pharmaceuticals™ Announces Second Quarter 2020 Results Release Date and Conference Call Details
MISSISSAUGA, ON, July 27, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2020 financial results before markets open on Monday, August 10, 2020.
May 12, 2020 04:20 pm ET
Nuvo Pharmaceuticals® Announces Director Election Results of its Annual & Special Meeting of Shareholders
MISSISSAUGA, ON, May 12, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2020 Virtual Annual & Special Meeting of Shareholders held on May 11, 2020, all nominees listed in the management proxy circular dated March 27, 2020 were elected as directors of the Company.
May 12, 2020 04:20 pm ET
Nuvo Pharmaceuticals® Announces Director Election Results of its Annual & Special Meeting of Shareholders
MISSISSAUGA, ON, May 12, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2020 Virtual Annual & Special Meeting of Shareholders held on May 11, 2020, all nominees listed in the management proxy circular dated March 27, 2020 were elected as directors of the Company.
May 11, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results
٠ Q1 2020 Adjusted Total Revenue - $18.9 million ٠٠ Q1 2020 Adjusted EBITDA - $8.0 million ٠٠ Blexten Canadian Prescriptions Increased 54% Year-Over-Year ٠٠ Cambia Canadian Prescriptions Increased 30% Year-Over-Year ٠
May 11, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results
٠ Q1 2020 Adjusted Total Revenue - $18.9 million ٠٠ Q1 2020 Adjusted EBITDA - $8.0 million ٠٠ Blexten Canadian Prescriptions Increased 54% Year-Over-Year ٠٠ Cambia Canadian Prescriptions Increased 30% Year-Over-Year ٠
Apr 30, 2020 10:00 am ET
C-Suite At The Open: Jesse Ledger, Chief Executive Officer, Nuvo Pharmaceuticals Inc., tells his Company's Story. Filmed on April 24, 2020
TORONTO, April 30, 2020 /CNW/ -
Apr 27, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results Release Date and Virtual Annual & Special Meeting of Shareholders
MISSISSAUGA, ON, April 27, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its first quarter 2020 financial results before markets open on Monday, May 11, 2020.  The Company will review the results of the first quarter 2020 in conjunction with the Annual & Special Meeting of Shareholders (Meeting).  The Meeting will be held in a virtual-only format due to the continuing public health impact of the COVID-19
Apr 27, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results Release Date and Virtual Annual & Special Meeting of Shareholders
MISSISSAUGA, ON, April 27, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its first quarter 2020 financial results before markets open on Monday, May 11, 2020.  The Company will review the results of the first quarter 2020 in conjunction with the Annual & Special Meeting of Shareholders (Meeting).  The Meeting will be held in a virtual-only format due to the continuing public health impact of the CO
Mar 31, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces Approval of Takeda's Cabpirin Tablets in Japan, Triggering a US$2.0 Million Milestone Payment due in Q2 2020
- Takeda holds a non-exclusive license to Nuvo's Yosprala™ patent permitting it to market Capbirin in Japan -
Mar 31, 2020 07:30 am ET
Nuvo Pharmaceuticals® Announces Approval of Takeda's Cabpirin Tablets in Japan, Triggering a US$2.0 Million Milestone Payment due in Q2 2020
- Takeda holds a non-exclusive license to Nuvo's Yosprala™ patent permitting it to market Capbirin in Japan -
Mar 24, 2020 08:30 am ET
Virtual Conference for Life Sciences Companies and Investors Broadcast Live March 26, 2020
Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Mar 23, 2020 10:00 am ET
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum March 26th
- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com -
Mar 23, 2020 10:00 am ET
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum March 26th
- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com -
Mar 23, 2020 08:35 am ET
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum March 26th
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Jesse Ledger, Nuvo’s President & Chief Executive...
Mar 04, 2020 04:05 pm ET
Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States
MISSISSAUGA, ON, March 4, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Dr. Reddy's Laboratories Inc. (DRL) has launched its generic version of Vimovo in the United States.
Feb 27, 2020 04:05 pm ET
Nuvo Pharmaceuticals® Announces Health Canada Approves Suvexx™ For The Acute Treatment of Migraine
- Canadian Launch Anticipated in the Second Half of 2020 -
Feb 25, 2020 06:30 am ET
Nuvo Pharmaceuticals® Announces 2019 and Fourth Quarter Results
٠ Fiscal Year 2019 Adjusted Total Revenue - $74.7 million ٠٠ Fiscal Year 2019 Adjusted EBITDA - $27.2 million ٠٠ Blexten Canadian Prescriptions Increased 61% Year-Over-Year ٠٠ Cambia Canadian Prescriptions Increased 28% Year-Over-Year ٠
Feb 11, 2020 01:27 pm ET
Nuvo Pharmaceuticals™ Responds to Market Activity
MISSISSAUGA, ON, Feb. 11, 2020 /CNW/ - At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its common shares.
Feb 11, 2020 06:30 am ET
Nuvo Pharmaceuticals™ Announces Fourth Quarter 2019 Results Release Date and Conference Call Details
MISSISSAUGA, ON, Feb. 11, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its fourth quarter 2019 financial results before markets open on Tuesday, February 25, 2020.
Jan 07, 2020 06:30 am ET
Nuvo Pharmaceuticals™ Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty
MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the Company will repay its Bridge Loan to Deerfield Management Company, L.P. (Deerfield) during the second week of January and will receive the full US$7.5 million annual minimum royalty payment due from the 2019 sales of Vimovo in the U.S.  The Company has received US$5.6 million to-date.
Nov 11, 2019 06:30 am ET
Nuvo Pharmaceuticals™ Announces United States District Court Denies Dr. Reddy's Laboratories Motion for Summary Judgment of Nuvo's '996 and '920 VIMOVO Patents
VIMOVO Litigation to Continue
Nov 11, 2019 06:30 am ET
Nuvo Pharmaceuticals™ Announces United States District Court Denies Dr. Reddy's Laboratories Motion for Summary Judgment of Nuvo's '996 and '920 VIMOVO Patents
VIMOVO Litigation to Continue
Oct 31, 2019 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2019 Third Quarter Results
· Third Quarter Adjusted Total Revenue - $18.9 million and $55.1 million year-to-date ·· Third Quarter Adjusted EBITDA - $7.8 million and $18.7 million year-to-date ·· Third Quarter Gross Profit - $11.3 million and $30.0 million year-to date ·
Oct 31, 2019 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2019 Third Quarter Results
· Third Quarter Adjusted Total Revenue - $18.9 million and $55.1 million year-to-date ·· Third Quarter Adjusted EBITDA - $7.8 million and $18.7 million year-to-date ·· Third Quarter Gross Profit - $11.3 million and $30.0 million year-to date ·
Oct 17, 2019 08:00 am ET
Nuvo Pharmaceuticals™ Announces Third Quarter 2019 Results Release Date and Conference Call Details
MISSISSAUGA, ON, Oct. 17, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its third quarter 2019 financial results before markets open on Thursday, October 31, 2019.
Oct 17, 2019 08:00 am ET
Nuvo Pharmaceuticals™ Announces Third Quarter 2019 Results Release Date and Conference Call Details
MISSISSAUGA, ON, Oct. 17, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its third quarter 2019 financial results before markets open on Thursday, October 31, 2019.
Sep 09, 2019 08:00 am ET
Nuvo Pharmaceuticals™ Update to Nuvo's Presentation Time at H.C. Wainwright Global Investment Conference
- Tuesday, September 10, 2019 – 4:15 p.m. ET -
Sep 09, 2019 08:00 am ET
Nuvo Pharmaceuticals™ Update to Nuvo's Presentation Time at H.C. Wainwright Global Investment Conference
- Tuesday, September 10, 2019 – 4:15 p.m. ET -
Sep 04, 2019 08:00 am ET
Nuvo Pharmaceuticals™ to Present at H.C. Wainwright Global Investment Conference
MISSISSAUGA, ON, Sept. 4, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that Jesse Ledger, Nuvo's President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City.
Sep 04, 2019 08:00 am ET
Nuvo Pharmaceuticals™ to Present at H.C. Wainwright Global Investment Conference
MISSISSAUGA, ON, Sept. 4, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that Jesse Ledger, Nuvo's President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City.
Aug 14, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces 2019 Second Quarter Results
• Second Quarter Adjusted Total Revenue - $19.1 million •• Second Quarter Adjusted EBITDA - $5.7 million •• Second Quarter Gross Profit - $9.6 million •
Aug 14, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces 2019 Second Quarter Results
• Second Quarter Adjusted Total Revenue - $19.1 million •• Second Quarter Adjusted EBITDA - $5.7 million •• Second Quarter Gross Profit - $9.6 million •
Jul 31, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces Second Quarter 2019 Results Release Date and Conference Call Details
MISSISSAUGA, ON, July 31, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its second quarter 2019 financial results before markets open on Wednesday, August 14, 2019.
Jul 31, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces Second Quarter 2019 Results Release Date and Conference Call Details
MISSISSAUGA, ON, July 31, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its second quarter 2019 financial results before markets open on Wednesday, August 14, 2019.
Jul 30, 2019 10:50 am ET
Nuvo Pharmaceuticals™ Provides VIMOVO Patent Update
MISSISSAUGA, ON, July 30, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today provided an update regarding its VIMOVO patents.
Jul 30, 2019 10:50 am ET
Nuvo Pharmaceuticals™ Provides VIMOVO Patent Update
MISSISSAUGA, ON, July 30, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today provided an update regarding its VIMOVO patents.
Jun 26, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting and Updates to the Facility Agreement with Deerfield
MISSISSAUGA, ON, June 26, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2019 Annual Meeting of Shareholders held on June 25, 2019 in Mississauga, all nominees listed in the management proxy circular dated May 16, 2019 were elected as directors of the Company.
Jun 17, 2019 08:00 am ET
Nuvo Pharmaceuticals™ Provides Corporate Update
MISSISSAUGA, ON, June 17, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. ("Nuvo" or "the Company") (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today provided a corporate update on various matters including its VIMOVO patents, the identification of Aralez Transaction synergies and an update regarding the status of its financing arrangements with Deerfield Management Company, L.P. (Deerfield). All financial references are in Canadian dollars unless otherwise indicated.
May 15, 2019 01:25 pm ET
IIROC Trade Resumption - NRI
TORONTO, May 15, 2019 /CNW/ - Trading resumes in:
May 15, 2019 01:10 pm ET
Nuvo Pharmaceuticals™ Announces that U.S. Court of Appeals for the Federal Circuit Reverses District Court's Decision Related to Certain Vimovo Patents
MISSISSAUGA, ON, May 15, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that the United States Court of Appeals for the Federal Circuit reversed the decision by the United States District Court for the District of New Jersey related to certain Vimovo patents.  This ruling reverses the decision made on July 10, 2017 involving patents U.S. Patent Nos. 6,926,907 ("the '907 patent") and 8,557,285 ("the '285 patent").
May 15, 2019 01:10 pm ET
Nuvo Pharmaceuticals™ Announces that U.S. Court of Appeals for the Federal Circuit Reverses District Court's Decision Related to Certain Vimovo Patents
MISSISSAUGA, ON, May 15, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that the United States Court of Appeals for the Federal Circuit reversed the decision by the United States District Court for the District of New Jersey related to certain Vimovo patents.  This ruling reverses the decision made on July 10, 2017 involving patents U.S. Patent Nos. 6,926,907 ("the '907 patent") and 8,557,285 ("the '285 patent").
May 15, 2019 10:42 am ET
IIROC Trading Halt - NRI
TORONTO, May 15, 2019 /CNW/ - The following issues have been halted by IIROC:
May 14, 2019 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2019 First Quarter Results
- Adjusted Total Revenue Increased 278% to $17.1 million -- Adjusted EBITDA Increased 807% to $5.2 million -- Gross Profit Increased 259% to $9.0 million -- Successfully Integrating Aralez Canada into the Nuvo Business -
May 14, 2019 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2019 First Quarter Results
- Adjusted Total Revenue Increased 278% to $17.1 million -- Adjusted EBITDA Increased 807% to $5.2 million -- Gross Profit Increased 259% to $9.0 million -- Successfully Integrating Aralez Canada into the Nuvo Business -
Apr 23, 2019 07:30 am ET
Nuvo Pharmaceuticals™ to Present at the Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, ON, April 23, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products today announced that Jesse Ledger, the Company's President & Chief Executive Officer will be providing a corporate update at the Bloom Burton & Co Healthcare Investor Conference on Tuesday, April 30th - 2:00 p.m. at the Metro Toronto Convention Centre, 255 Front Street West, Toronto.
Apr 23, 2019 07:30 am ET
Nuvo Pharmaceuticals™ to Present at the Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, ON, April 23, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products today announced that Jesse Ledger, the Company's President & Chief Executive Officer will be providing a corporate update at the Bloom Burton & Co Healthcare Investor Conference on Tuesday, April 30th - 2:00 p.m. at the Metro Toronto Convention Centre, 255 Front Street West, Toronto.
Apr 02, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces Pennsaid 2% Marketing Authorization Application Accepted for Review by AGES, the Austrian Agency for Health and Food Safety
MISSISSAUGA, ON, April 2, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the Marketing Authorization Application for Pennsaid 2% cutaneous solution (Pennsaid 2%) that is indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee, has been accepted for review by the Austrian Agency for Health and Food Safety (AGES) acting as the reference member state.  Included in this decen
Apr 02, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces Pennsaid 2% Marketing Authorization Application Accepted for Review by AGES, the Austrian Agency for Health and Food Safety
MISSISSAUGA, ON, April 2, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the Marketing Authorization Application for Pennsaid 2% cutaneous solution (Pennsaid 2%) that is indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee, has been accepted for review by the Austrian Agency for Health and Food Safety (AGES) acting as the reference member state.  Included in thi
Mar 29, 2019 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2018 Fourth Quarter and Year-End Results
- Nuvo to Host Conference Call/Audio Webcast March 29th at 8:00 a.m. ET -
Mar 29, 2019 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2018 Fourth Quarter and Year-End Results
- Nuvo to Host Conference Call/Audio Webcast March 29th at 8:00 a.m. ET -
Mar 15, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces the Filing of the Business Acquisition Report Related to the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related As
MISSISSAUGA, ON, March 15, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF) today announced the filing of the Business Acquisition Report (BAR) on SEDAR (www.sedar.com) related to the previously announced acquisition of a portfolio of more than 20 revenue-generating products, as well as the associated personnel and infrastructure to continue the products' management and growth from Aralez Pharmaceuticals Inc. (Aralez) that closed on December 31, 2018.
Mar 15, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces the Filing of the Business Acquisition Report Related to the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related As
MISSISSAUGA, ON, March 15, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF) today announced the filing of the Business Acquisition Report (BAR) on SEDAR (www.sedar.com) related to the previously announced acquisition of a portfolio of more than 20 revenue-generating products, as well as the associated personnel and infrastructure to continue the products' management and growth from Aralez Pharmaceuticals Inc. (Aralez) that closed on December 31, 2018.
Mar 11, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces Receipt of Shareholder Approval By Way of Written Consent For the Issuance of Common Shares Pursuant to Convertible Notes and Warrants
MISSISSAUGA, ON, March 11, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF) today announced that it has obtained consents from shareholders of the Company (Shareholders) holding, in the aggregate, more than 50% of the Company's issued and outstanding common shares (Common Shares), approving the issuance by the Company of Common Shares pursuant to the conversion of convertible notes (Convertible Notes) and the exercise of warrants (Warrants), which were issued to certain funds managed by Deerfield Management Company, L.P. in connection with the previously an
Mar 11, 2019 07:30 am ET
Nuvo Pharmaceuticals™ Announces Receipt of Shareholder Approval By Way of Written Consent For the Issuance of Common Shares Pursuant to Convertible Notes and Warrants
MISSISSAUGA, ON, March 11, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF) today announced that it has obtained consents from shareholders of the Company (Shareholders) holding, in the aggregate, more than 50% of the Company's issued and outstanding common shares (Common Shares), approving the issuance by the Company of Common Shares pursuant to the conversion of convertible notes (Convertible Notes) and the exercise of warrants (Warrants), which were issued to certain funds managed by Deerfield Management Company, L.P. in connection with the previo
Jan 03, 2019 06:30 am ET
Nuvo Pharmaceuticals™ Announces Appointment of Rob Harris as Executive Chairman
MISSISSAUGA, ON, Jan. 3, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX : NRI; OTCQX : NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Rob Harris as its Executive Chairman.  Mr. Harris joined Nuvo's board of directors in May 2017 and was previously the co-founder and Chief Executive Officer of Tribute Pharmaceuticals Inc. (Tribute), formerly a Toronto Stock Exchange listed company.  Tribute was purchased in 2016 by Aralez Pharmaceuticals Inc., renamed Aralez Canada Inc.
Jan 03, 2019 06:30 am ET
Nuvo Pharmaceuticals™ Announces Appointment of Rob Harris as Executive Chairman
MISSISSAUGA, ON, Jan. 3, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX : NRI; OTCQX : NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Rob Harris as its Executive Chairman.  Mr. Harris joined Nuvo's board of directors in May 2017 and was previously the co-founder and Chief Executive Officer of Tribute Pharmaceuticals Inc. (Tribute), formerly a Toronto Stock Exchange listed company.  Tribute was purchased in 2016 by Aralez Pharmaceuticals Inc., renamed Aralez Canad
Jan 02, 2019 06:30 am ET
Nuvo Pharmaceuticals™ to Host Conference Call/Audio Webcast to Discuss the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
- January 2 at 8:30 a.m. ET -  
Jan 02, 2019 06:30 am ET
Nuvo Pharmaceuticals™ to Host Conference Call/Audio Webcast to Discuss the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
- January 2 at 8:30 a.m. ET -  
Dec 31, 2018 10:26 am ET
Nuvo Pharmaceuticals™ Announces Completion of the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
- Acquisition expected to result in significant expansion of revenue and adjusted EBITDA -- Acquisition includes more than 20 revenue-generating products -- Acquisition expected to provide platform for future growth -- Acquisition financing provided by Deerfield Management Company, L.P., a leading, global, healthcare-specialized investor -
Dec 31, 2018 10:26 am ET
Nuvo Pharmaceuticals™ Announces Completion of the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
- Acquisition expected to result in significant expansion of revenue and adjusted EBITDA -- Acquisition includes more than 20 revenue-generating products -- Acquisition expected to provide platform for future growth -- Acquisition financing provided by Deerfield Management Company, L.P., a leading, global, healthcare-specialized investor -
Dec 21, 2018 07:30 am ET
Nuvo Pharmaceuticals™ (Ireland) DAC Enters into Resultz® License and Supply Agreement with Heumann Pharma GmbH & Co. Generica KG for Germany
MISSISSAUGA, ON, Dec. 21, 2018 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC (Nuvo Ireland) has entered into a license and supply agreement (License Agreement) with Heumann Pharma GmbH & Co. Generica KG (Heumann) for the exclusive right to distribute, market and sell Resultz® in Germany (the Territory).  Heumann is headquartered in Nuremberg, Germ
Dec 21, 2018 07:30 am ET
Nuvo Pharmaceuticals™ (Ireland) DAC Enters into Resultz® License and Supply Agreement with Heumann Pharma GmbH & Co. Generica KG for Germany
MISSISSAUGA, ON, Dec. 21, 2018 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC (Nuvo Ireland) has entered into a license and supply agreement (License Agreement) with Heumann Pharma GmbH & Co. Generica KG (Heumann) for the exclusive right to distribute, market and sell Resultz® in Germany (the Territory).  Heumann is headquartered in Nurember
Nov 29, 2018 08:00 am ET
Nuvo Pharmaceuticals™ Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
- Transaction subject to court approval and other customary conditions -- Closing anticipated by year end -
Nov 29, 2018 08:00 am ET
Nuvo Pharmaceuticals™ Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
- Transaction subject to court approval and other customary conditions -- Closing anticipated by year end -
Nov 08, 2018 06:30 am ET
Nuvo Pharmaceuticals™ Announces 2018 Third Quarter Results
- Nuvo to Host Conference Call/Audio Webcast November 8th at 8:30 a.m. ET -
Nov 08, 2018 06:30 am ET
Nuvo Pharmaceuticals™ Announces 2018 Third Quarter Results
- Nuvo to Host Conference Call/Audio Webcast November 8th at 8:30 a.m. ET -
Sep 19, 2018 07:02 am ET
Nuvo Pharmaceuticals™ Announces Signing of Definitive Agreements to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
– Would result in significant expansion of revenue and adjusted EBITDA –
Sep 19, 2018 07:02 am ET
Nuvo Pharmaceuticals™ Announces Signing of Definitive Agreements to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
– Would result in significant expansion of revenue and adjusted EBITDA –
Aug 20, 2018 07:30 am ET
Nuvo Pharmaceuticals™ Announces Extension of Exclusivity Period with Aralez and Deerfield
MISSISSAUGA, ON, Aug. 20, 2018 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that it has extended the period of exclusive negotiations with Aralez Pharmaceuticals Inc. (Aralez) and Deerfield Management Company, L.P. (Deerfield) relating to the previously announced proposed acquisition by Nuvo of a portfolio of more than 20 revenue-generating products, as well as the associated personnel and infrastructure, from Aral
Aug 20, 2018 07:30 am ET
Nuvo Pharmaceuticals™ Announces Extension of Exclusivity Period with Aralez and Deerfield
MISSISSAUGA, ON, Aug. 20, 2018 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that it has extended the period of exclusive negotiations with Aralez Pharmaceuticals Inc. (Aralez) and Deerfield Management Company, L.P. (Deerfield) relating to the previously announced proposed acquisition by Nuvo of a portfolio of more than 20 revenue-generating products, as well as the associated personnel and infrastructure, fr
Aug 10, 2018 06:19 am ET
Nuvo Pharmaceuticals™ Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
- Would result in significant expansion of revenue and adjusted EBITDA –
Aug 10, 2018 06:19 am ET
Nuvo Pharmaceuticals™ Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
- Would result in significant expansion of revenue and adjusted EBITDA –
Aug 02, 2018 07:30 am ET
Nuvo Pharmaceuticals™ Announces 2018 Second Quarter Results
- Reports $1.9 million of Adjusted EBITDA on $5.9 million of Revenue -- Finished the Quarter with $8.7 million of Cash and no Debt -
Aug 02, 2018 07:30 am ET
Nuvo Pharmaceuticals™ Announces 2018 Second Quarter Results
- Reports $1.9 million of Adjusted EBITDA on $5.9 million of Revenue -- Finished the Quarter with $8.7 million of Cash and no Debt -
Jul 23, 2018 07:15 am ET
Nuvo Pharmaceuticals™(Ireland) Limited Enters into Resultz® License and Supply Agreement with Fagron Belgium NV for Belgium, the Netherlands and Luxembourg
Jul 23, 2018 07:15 am ET
Nuvo Pharmaceuticals™(Ireland) Limited Enters into Resultz® License and Supply Agreement with Fagron Belgium NV for Belgium, the Netherlands and Luxembourg
May 10, 2018 05:13 pm ET
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
MISSISSAUGA, ON, May 10, 2018 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2018 Annual and Special Meeting of Shareholders held on May 10, 2018 in Mississauga, all nominees listed in the management proxy circular dated March 29, 2018 were elected as directors of the Company.
May 10, 2018 05:13 pm ET
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
MISSISSAUGA, ON, May 10, 2018 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2018 Annual and Special Meeting of Shareholders held on May 10, 2018 in Mississauga, all nominees listed in the management proxy circular dated March 29, 2018 were elected as directors of the Company.
May 10, 2018 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2018 First Quarter Results
- Nuvo to Host Conference Call/Audio Webcast May 10th at 7:45 a.m. ET -
May 10, 2018 07:00 am ET
Nuvo Pharmaceuticals™ Announces 2018 First Quarter Results
- Nuvo to Host Conference Call/Audio Webcast May 10th at 7:45 a.m. ET -
Apr 16, 2018 08:35 am ET
Nuvo Pharmaceuticals Inc. Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Apr 16, 2018 08:35 am ET
Nuvo Pharmaceuticals Inc. Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Apr 09, 2018 08:35 am ET
Nuvo Pharmaceuticals Inc. to Webcast, Live, at VirtualInvestorConferences.com April 11, 2018
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Apr 09, 2018 08:35 am ET
Nuvo Pharmaceuticals Inc. to Webcast, Live, at VirtualInvestorConferences.com April 11, 2018
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Apr 06, 2018 09:05 am ET
OTC Markets Group Announces Agenda for OTCQX International Virtual Investor Conference on April 11-12
NEW YORK, April 6, 2018 /CNW/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its next OTCQX® Virtual Investor Conference on April 11-12, 2018 featuring leading International companies trading on the OTCQX Best Market. 
Apr 06, 2018 09:05 am ET
OTC Markets Group Announces Agenda for OTCQX International Virtual Investor Conference on April 11-12
NEW YORK, April 6, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its next OTCQX® Virtual Investor Conference on April 11-12, 2018 featuring leading International companies trading on the OTCQX Best Market. 
Mar 23, 2018 08:00 am ET
Nuvo Pharmaceuticals™ Announces 2017 Fourth Quarter and Year-End Results
- Nuvo to Host Conference Call/Audio Webcast March 23 at 8:30 a.m. ET -
Mar 23, 2018 08:00 am ET
Nuvo Pharmaceuticals™ Announces 2017 Fourth Quarter and Year-End Results
- Nuvo to Host Conference Call/Audio Webcast March 23 at 8:30 a.m. ET -
Jan 15, 2018 06:30 am ET
Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC
Resultz was FDA cleared in May 2017 - Company now owns Resultz product rights globally -- Opens access to ~US$255 million head lice market -
Jan 15, 2018 06:30 am ET
Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC
Resultz was FDA cleared in May 2017 - Company now owns Resultz product rights globally -- Opens access to ~US$255 million head lice market -
Jan 02, 2018 06:30 am ET
Nuvo Pharmaceuticals Inc.™ Acquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz® from Piedmont Pharmaceuticals LLC
- US$7.0 million purchase price funded from existing cash -- Immediately accretive acquisition -
Jan 02, 2018 06:30 am ET
Nuvo Pharmaceuticals Inc.™ Acquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz® from Piedmont Pharmaceuticals LLC
- US$7.0 million purchase price funded from existing cash -- Immediately accretive acquisition -
Dec 14, 2017 06:30 am ET
Nuvo Pharmaceuticals™ Enters into Pennsaid® 2% License Agreement with Gebro Pharma AG for Switzerland and Liechtenstein
MISSISSAUGA, ON, Dec. 14, 2017 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced it has entered into a license and distribution agreement (License Agreement) with Gebro Pharma AG (Gebro Pharma) for the exclusive right to register, distribute, market and sell Pennsaid® 2% in Switzerland and Liechtenstein (the Territory).  Gebro Pharma AG is the Switzerland-based affiliate of Gebro Holding GmbH, an Austrian-based pharmaceutical c
Dec 14, 2017 06:30 am ET
Nuvo Pharmaceuticals™ Enters into Pennsaid® 2% License Agreement with Gebro Pharma AG for Switzerland and Liechtenstein
MISSISSAUGA, ON, Dec. 14, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced it has entered into a license and distribution agreement (License Agreement) with Gebro Pharma AG (Gebro Pharma) for the exclusive right to register, distribute, market and sell Pennsaid® 2% in Switzerland and Liechtenstein (the Territory).  Gebro Pharma AG is the Switzerland-based affiliate of Gebro Holding GmbH, an Austrian-based pharmaceu
Nov 30, 2017 06:30 am ET
Nuvo Pharmaceuticals™ Announces Normal Course Issuer Bid
MISSISSAUGA, ON, Nov. 30, 2017 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, announced today that the Toronto Stock Exchange (TSX) has approved its notice of intention to make a normal course issuer bid for a portion of its outstanding common shares as appropriate opportunities arise from time-to-time.  The normal course issuer bid will be made in accordance with the requirements of the TSX.  Nuvo believes that the repurchase of a portion
Nov 30, 2017 06:30 am ET
Nuvo Pharmaceuticals™ Announces Normal Course Issuer Bid
MISSISSAUGA, ON, Nov. 30, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, announced today that the Toronto Stock Exchange (TSX) has approved its notice of intention to make a normal course issuer bid for a portion of its outstanding common shares as appropriate opportunities arise from time-to-time.  The normal course issuer bid will be made in accordance with the requirements of the TSX.  Nuvo believes that the repurchase of a p
Nov 28, 2017 06:00 am ET
Nuvo Pharmaceuticals™ Commences Trading on the OTCQX® Market in the U.S.
MISSISSAUGA, ON, Nov. 28, 2017 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that effective immediately, the Company's common shares will commence trading on the OTCQX® market in the United States under the symbol "NRIFF".  Nuvo's common shares will continue to trade on the Toronto Stock Exchange under the symbol "NRI".
Nov 28, 2017 06:00 am ET
Nuvo Pharmaceuticals™ Commences Trading on the OTCQX® Market in the U.S.
MISSISSAUGA, ON, Nov. 28, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that effective immediately, the Company's common shares will commence trading on the OTCQX® market in the United States under the symbol "NRIFF".  Nuvo's common shares will continue to trade on the Toronto Stock Exchange under the symbol "NRI".
Nov 28, 2017 06:00 am ET
OTC Markets Group Welcomes Nuvo Pharmaceuticals to OTCQX
NEW YORK, Nov. 28, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Nuvo Pharmaceuticals Inc (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company, has qualified to trade on OTCQX® Best Market.  Nuvo Pharmaceuticals upgraded to OTCQX from the Pink® market.
Nov 22, 2017 04:15 pm ET
Nuvo Pharmaceuticals™ Announces Appointment of Jesse Ledger as President & Chief Executive Officer
MISSISSAUGA, ON, Nov. 22, 2017 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced the appointment of Jesse Ledger as its President & Chief Executive Officer.  Mr. Ledger was previously President of the Company.  Mr. Ledger assumes the CEO role from John London who will become the Company's Executive Chairman and continue to serve on its board of directors.  Dan Chicoine, previously Chairman of the Company, will continue as a member of the
Nov 22, 2017 04:15 pm ET
Nuvo Pharmaceuticals™ Announces Appointment of Jesse Ledger as President & Chief Executive Officer
MISSISSAUGA, ON, Nov. 22, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced the appointment of Jesse Ledger as its President & Chief Executive Officer.  Mr. Ledger was previously President of the Company.  Mr. Ledger assumes the CEO role from John London who will become the Company's Executive Chairman and continue to serve on its board of directors.  Dan Chicoine, previously Chairman of the Company, will continue as a member
Nov 01, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2017 Third Quarter Results
- Pennsaid 2% U.S. Q3 prescriptions remain steady -
Nov 01, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2017 Third Quarter Results
- Pennsaid 2% U.S. Q3 prescriptions remain steady -
Aug 24, 2017 08:30 am ET
Nuvo Pharmaceuticals™ Secures Credit Facility from the Royal Bank of Canada
MISSISSAUGA, ON, Aug. 24, 2017 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that it has secured a $6.0 million operating revolving credit facility (Facility) with Royal Bank of Canada (RBC). The Facility is a standby Facility that can be drawn by Nuvo for working capital requirements and general corporate purposes. Nuvo has not currently drawn any amount of the Facility.
Aug 24, 2017 08:30 am ET
Nuvo Pharmaceuticals™ Secures Credit Facility from the Royal Bank of Canada
MISSISSAUGA, ON, Aug. 24, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that it has secured a $6.0 million operating revolving credit facility (Facility) with Royal Bank of Canada (RBC). The Facility is a standby Facility that can be drawn by Nuvo for working capital requirements and general corporate purposes. Nuvo has not currently drawn any amount of the Facility.
Aug 09, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2017 Second Quarter Results
- Pennsaid® 2% U.S. prescriptions increased from Q1 -
Aug 09, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2017 Second Quarter Results
- Pennsaid® 2% U.S. prescriptions increased from Q1 -
May 15, 2017 08:35 am ET
Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%
- Pennsaid 2% Already Approved for Marketing in the United States and Russia -
May 15, 2017 08:35 am ET
Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%
- Pennsaid 2% Already Approved for Marketing in the United States and Russia -
May 15, 2017 08:30 am ET
Nuvo Pharmaceuticals™ Announces District Court Decision to Uphold U.S. Pennsaid® 2% Patent
- U.S. Patent Covering Pennsaid® 2% Infringed by a Proposed Generic Developed by Actavis Laboratories UT, Inc. -    
May 15, 2017 08:30 am ET
Nuvo Pharmaceuticals™ Announces District Court Decision to Uphold U.S. Pennsaid® 2% Patent
- U.S. Patent Covering Pennsaid® 2% Infringed by a Proposed Generic Developed by Actavis Laboratories UT, Inc. -    
May 11, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
MISSISSAUGA, ON, May 11, 2017 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2017 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 5, 2017 were elected as directors of the Company.
May 11, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
MISSISSAUGA, ON, May 11, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2017 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 5, 2017 were elected as directors of the Company.
May 10, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2017 First Quarter Results
Reports Q1 Revenue of $7.0 million and Net Income of $2.2 million
May 10, 2017 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2017 First Quarter Results
Reports Q1 Revenue of $7.0 million and Net Income of $2.2 million
Mar 28, 2017 08:30 am ET
Nuvo Pharmaceuticals™ Enters into Pennsaid® 2% License Agreement with Sayre Therapeutics PVT Ltd. for India, Sri Lanka, Bangladesh and Nepal
MISSISSAUGA, ON, March 28, 2017 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that it has entered into an exclusive license agreement with Sayre Therapeutics PVT Ltd. (Sayre Therapeutics) to distribute, market and sell Pennsaid 2% in India, Sri Lanka, Bangladesh and Nepal (the Territory).  Nuvo has received an upfront payment and is eligible to receive milestone payments and a double-digit royalty on net sales.  Nuvo will supply Pennsaid
Mar 28, 2017 08:30 am ET
Nuvo Pharmaceuticals™ Enters into Pennsaid® 2% License Agreement with Sayre Therapeutics PVT Ltd. for India, Sri Lanka, Bangladesh and Nepal
MISSISSAUGA, ON, March 28, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that it has entered into an exclusive license agreement with Sayre Therapeutics PVT Ltd. (Sayre Therapeutics) to distribute, market and sell Pennsaid 2% in India, Sri Lanka, Bangladesh and Nepal (the Territory).  Nuvo has received an upfront payment and is eligible to receive milestone payments and a double-digit royalty on net sales.  Nuvo will supply Pe
Mar 01, 2017 05:00 pm ET
Nuvo Pharmaceuticals™ Announces 2016 Year-End and Fourth Quarter Results
- Reports 32% Year-Over-Year Revenue Growth -
Mar 01, 2017 05:00 pm ET
Nuvo Pharmaceuticals™ Announces 2016 Year-End and Fourth Quarter Results
- Reports 32% Year-Over-Year Revenue Growth -
Nov 16, 2016 07:30 am ET
Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger as President
MISSISSAUGA, ON, Nov. 16, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), formerly Nuvo Research Inc., a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that its board of directors has appointed Jesse Ledger to the position of President effective immediately.
Nov 16, 2016 07:30 am ET
Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger as President
MISSISSAUGA, ON, Nov. 16, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), formerly Nuvo Research Inc., a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that its board of directors has appointed Jesse Ledger to the position of President effective immediately.
Nov 10, 2016 05:30 pm ET
Nuvo Pharmaceuticals™ Announces 2016 Third Quarter Results
- Nuvo continues to generate net income and cash from operating activities -
Nov 10, 2016 05:30 pm ET
Nuvo Pharmaceuticals™ Announces 2016 Third Quarter Results
- Nuvo continues to generate net income and cash from operating activities -
Oct 17, 2016 08:30 am ET
Nuvo Pharmaceuticals™ Receives Approval from German Regulatory Authorities to Conduct Pennsaid® 2% Phase 3 Trial for Treatment of Acute Ankle Sprains
- Trial Results Expected Q2 2017 -
Oct 17, 2016 08:30 am ET
Nuvo Pharmaceuticals™ Receives Approval from German Regulatory Authorities to Conduct Pennsaid® 2% Phase 3 Trial for Treatment of Acute Ankle Sprains
- Trial Results Expected Q2 2017 -
Sep 01, 2016 05:30 pm ET
Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer
MISSISSAUGA, ON, Sept. 1, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer.  Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller.  She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration  Degree from the Ivey Business School, University
Sep 01, 2016 05:30 pm ET
Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer
MISSISSAUGA, ON, Sept. 1, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer.  Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller.  She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration  Degree from the Ivey Business School, Uni
Aug 10, 2016 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2016 Second Quarter Results
- Q2 net income increases to $2.5 million or $0.22 basic earnings per share -- Positive cash from operating activities of $2.1 million in the quarter -
Aug 10, 2016 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2016 Second Quarter Results
- Q2 net income increases to $2.5 million or $0.22 basic earnings per share -- Positive cash from operating activities of $2.1 million in the quarter -
Jul 13, 2016 08:30 am ET
Nuvo Pharmaceuticals™ Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia
MISSISSAUGA, ON, July 13, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial (Trial) in Germany to study Pennsaid 2% for the treatment of acute ankle sprains.  Topline results of the Trial are expected to be available in late Q2 or early Q3 2017.  The Trial is subject to approval by German regulatory authorities and the ethical review committee.  Pennsaid 2% is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of the pain of osteoarthritis of the knee(s).
Jul 13, 2016 08:30 am ET
Nuvo Pharmaceuticals™ Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia
MISSISSAUGA, ON, July 13, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial (Trial) in Germany to study Pennsaid 2% for the treatment of acute ankle sprains.  Topline results of the Trial are expected to be available in late Q2 or early Q3 2017.  The Trial is subject to approval by German regulatory authorities and the ethical review committee.  Pennsaid 2% is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of the pain of osteoarthritis of the k
Jun 07, 2016 04:42 pm ET
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
MISSISSAUGA, ON, June 7, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
Jun 07, 2016 04:42 pm ET
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
MISSISSAUGA, ON, June 7, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
May 11, 2016 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results
- Revenue and gross margin increase -- Nuvo to Host Conference Call/Audio Webcast May 12th at 8:30 a.m. ET -
May 11, 2016 06:00 pm ET
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results
- Revenue and gross margin increase -- Nuvo to Host Conference Call/Audio Webcast May 12th at 8:30 a.m. ET -
Apr 04, 2016 08:30 am ET
Nuvo Pharmaceuticals™ Inc. announces appointment of Vice President, Business Development
MISSISSAUGA, ON, April 4, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced that Jesse Ledger has been appointed to the newly created position of Vice President, Business Development.  Mr. Ledger will be responsible for all business development activities with an initial focus on maximizing the value of the Company's Pennsaid 2% franchise through global out-licensing.
Apr 04, 2016 08:30 am ET
Nuvo Pharmaceuticals™ Inc. announces appointment of Vice President, Business Development
MISSISSAUGA, ON, April 4, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced that Jesse Ledger has been appointed to the newly created position of Vice President, Business Development.  Mr. Ledger will be responsible for all business development activities with an initial focus on maximizing the value of the Company's Pennsaid 2% franchise through global out-licensing.
Mar 07, 2016 09:00 am ET
Nuvo Pharmaceuticals™ Inc. Announces Results from European Ankle Sprain Study with Pennsaid® 2%
 - Pennsaid 2% Already Approved for Osteoarthritis of the Knee in the United States -
Mar 07, 2016 09:00 am ET
Nuvo Pharmaceuticals™ Inc. Announces Results from European Ankle Sprain Study with Pennsaid® 2%
 - Pennsaid 2% Already Approved for Osteoarthritis of the Knee in the United States -
Mar 01, 2016 07:30 am ET
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies
- Nuvo Pharmaceuticals Inc. and Crescita Therapeutics Inc. to commence independent trading on March 7, 2016 -
Mar 01, 2016 07:30 am ET
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies
- Nuvo Pharmaceuticals Inc. and Crescita Therapeutics Inc. to commence independent trading on March 7, 2016 -
Feb 24, 2016 05:00 pm ET
Nuvo Research® Inc. Obtains Final Court Order Approving Reorganization into Two Publicly-Traded Companies
MISSISSAUGA, ON, Feb. 24, 2016 /CNW/ - Nuvo Research Inc. (TSX:NRI) (Nuvo or the Company) is pleased to announce that the Company has obtained a final court order from the Ontario Superior Court of Justice approving the reorganization of Nuvo into two separate publicly traded companies. The reorganization was approved by Nuvo shareholders at a special shareholders meeting on February 18, 2016.
Feb 24, 2016 05:00 pm ET
Nuvo Research® Inc. Obtains Final Court Order Approving Reorganization into Two Publicly-Traded Companies
MISSISSAUGA, ON, Feb. 24, 2016 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI) (Nuvo or the Company) is pleased to announce that the Company has obtained a final court order from the Ontario Superior Court of Justice approving the reorganization of Nuvo into two separate publicly traded companies. The reorganization was approved by Nuvo shareholders at a special shareholders meeting on February 18, 2016.
Feb 18, 2016 02:38 pm ET
Nuvo Research® Shareholders Approve Proposed Reorganization into Two Separate Public Companies
MISSISSAUGA, ON, Feb. 18, 2016 /CNW/ - Nuvo Research Inc. (TSX:NRI) ("Nuvo" or the "Company"), a life sciences company with growing revenues and a diverse portfolio of topical products, is pleased to announce that the proposed reorganization of Nuvo into two separate publicly traded companies, Nuvo Pharmaceuticals Inc. (Nuvo Pharma), a revenue and EBITDA generating commercial healthcare company, and Crescita Therapeutics Inc. (Crescita), a drug development company, was approved by Nuvo's shareholders shares at today's special meeting.  The exact number of votes cast for and against each of t
Feb 18, 2016 02:38 pm ET
Nuvo Research® Shareholders Approve Proposed Reorganization into Two Separate Public Companies
MISSISSAUGA, ON, Feb. 18, 2016 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI) ("Nuvo" or the "Company"), a life sciences company with growing revenues and a diverse portfolio of topical products, is pleased to announce that the proposed reorganization of Nuvo into two separate publicly traded companies, Nuvo Pharmaceuticals Inc. (Nuvo Pharma), a revenue and EBITDA generating commercial healthcare company, and Crescita Therapeutics Inc. (Crescita), a drug development company, was approved by Nuvo's shareholders shares at today's special meeting.  The exact number of votes cast for and against ea
Feb 17, 2016 05:00 pm ET
Nuvo Research® Announces 2015 Fourth Quarter & Year-End Results
- Quarter Highlighted by growth in Product Sales and Gross Margin -
Feb 17, 2016 05:00 pm ET
Nuvo Research® Announces 2015 Fourth Quarter & Year-End Results
- Quarter Highlighted by growth in Product Sales and Gross Margin -
Feb 08, 2016 07:30 am ET
Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement
MISSISSAUGA, ON, Feb. 8, 2016 /CNW/ - Nuvo Research Inc. (TSX:NRI), a life sciences company with growing revenues and a diverse portfolio of topical products, today announced it has agreed with Horizon Pharma plc (NASDAQ:HZNP) (Horizon) to extend the term of their manufacturing agreement for the production of PENNSAID® 2% for the U.S. market to December 31, 2029, which extends the agreement by an additional seven years.  The amended agreement also provides for tiered pricing based on volumes of product supplied.
Feb 08, 2016 07:30 am ET
Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement
MISSISSAUGA, ON, Feb. 8, 2016 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a life sciences company with growing revenues and a diverse portfolio of topical products, today announced it has agreed with Horizon Pharma plc (NASDAQ:HZNP) (Horizon) to extend the term of their manufacturing agreement for the production of PENNSAID® 2% for the U.S. market to December 31, 2029, which extends the agreement by an additional seven years.  The amended agreement also provides for tiered pricing based on volumes of product supplied.
Jan 21, 2016 07:30 am ET
Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End
MISSISSAUGA, Jan. 21, 2016 /CNW/ - Nuvo Research Inc. (TSX:NRI), a life sciences company with growing revenues and a diverse portfolio of topical products, today provided unaudited estimated total revenue for the fourth quarter and full year ended December 31, 2015.  All amounts referenced herein are in Canadian dollars.
Jan 21, 2016 07:30 am ET
Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End
MISSISSAUGA, Jan. 21, 2016 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a life sciences company with growing revenues and a diverse portfolio of topical products, today provided unaudited estimated total revenue for the fourth quarter and full year ended December 31, 2015.  All amounts referenced herein are in Canadian dollars.